Year 2019

• Epigenetic inhibitor zebularine activates ear pinna wound closure in the mouse

  Publication

  • P. Sass
  • P. Sosnowski
  • J. Podolak-Popinigis
  • B. Górnikiewicz
  • J. Kamińska
  • M. Deptuła
  • E. Nowicka
  • A. Wardowska
  • J. Ruczyński
  • P. Rekowski... and 12 others

  - EBioMedicine - Year 2019

  Background:Most studies on regenerative medicine focus on cell-based therapies and transplantations.Small-molecule therapeutics, though proved effective in different medical conditions, have not been extensivelyinvestigated in regenerative research. It is known that healing potential decreases with development and devel-opmental changes are driven by epigenetic mechanisms, which suggests epigenetic repression of regenerativecapacity.Methods:We...

  Full text available to download

Year 2011

• Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis

  Publication

  • J. Paradziej-Łukowicz
  • A. Skwarska
  • G. Peszyńska-Sularz
  • A. Brillowska-Dąbrowska
  • J. Konopa

  - CANCER BIOLOGY & THERAPY - Year 2011

  Antitumor imidazoacridinone C-1311 is a DNA-reactive topoisomerase II and FLT3 receptor tyrosine kinase inhibitor. Here, we demonstrate the mechanism of C-1311 inhibitory action on novel targets: hypoxia-inducible factor-1α (HIF-1α), vascular-endothelial growth factor (VEGF), and angiogenesis. In a cell-free system, C-1311 prevented HIF-1α binding to an oligonucleotide encompassing a canonical hypoxia-responsive element (HRE),...

  Full text available to download

• DNA-reactive anticancer imidazoacridinone C-1311 is a new inhibitor of hypoxia-inducible factor 1 alpha, vascular endothelial growth factor and tumor angiogenesis

  Publication

  • A. Skwarska
  • J. Paradziej-Łukowicz
  • G. Peszyńska-Sularz
  • A. Brillowska-Dąbrowska
  • J. Konopa

  - ANNALS OF ONCOLOGY - Year 2011

  Hypoxia-inducible factor 1 (HIF-1) plays a critical role for tumor adaptation to hypoxia and promotes angiogenesis. Antitumor imidazoacridinone C-1311 is a DNA reactive topoisomerase II and FLT3 receptor tyrosine kinase inhibitor selected for phase II clinical trials for breast cancer. Here, we demonstrate the new mechanism of C-1311 action involving HIF-1a, vascular endothelial growth factor (VEGF) and angiogenesis as additional...

  Full text to download in external service

Year 2006

• Dietary intervention with red beet juice ameliorates side effects resulting from oxidative stress during cancer chemotherapy with doxorubicin

  Publication

  • J. Paradziej-Łukowicz
  • G. Peszyńska-Sularz
  • A. Cieślak
  • A. Piasek
  • S. Popadiuk
  • W. Grajek
  • A. Bartoszek-Pączkowska

  - Acta Biochimica Polonica - Year 2006

  Chemoterapia nowotworów wiąże się ze stymulacją stresu oksydacyjnego, wywołującego niekorzystne efekty uboczne w organizmie. Panuje pogląd, że wprowadzenie do terapii przeciwutleniaczy może te niekorzystne efekty uboczne zmniejszyć. W naszych badaniach jako źródło utleniaczy wykorzystaliśmy sok z buraka ćwikłowego. Pokazaliśmy, że jego zastosowanie w kombinacji z lekiem przeciwnowotworowym doksorubicyną znacznie poprawia efekty...